VIVET THERAPEUTICS ATTENDING JEFFERIES 2025 – LONDON HEALTHCARE CONFERENCE
Vivet Therapeutics is pleased to announce that our CEO, Jean-Philippe Combal, will be attending the Jefferies Global Healthcare Conference in London from November 18th to 20th, 2025. As we join this leading global event, we are excited to present our latest advances, including the VTX-PID NAb depleting strategy. VTX-PID is designed to temporarily reduce anti-AAV […]
Vivet Therapeutics Presents Breakthrough Data on AAV Neutralizing Antibody Depletion at ESGCT 2025
Sevilla, October 2025 – At the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Vivet Therapeutics shared new clinical data with its VTX-PID proprietary imlifidase formulation, highlighting the effective reduction of neutralizing antibodies (NAbs) against AAV3B in healthy volunteers. Key Findings: Vivet Therapeutics remains committed to advancing innovative therapies and […]
Join our CEO, @Jean-Philippe Combal in the BigApple for @Chardan’s 9th Annual Genetic Medicines Conference!
Join our CEO, @Jean-Philippe Combal in the Big Apple for @Chardan’s 9th Annual Genetic Medicines Conference! The premier event will bring together groundbreaking thought leaders to discuss major themes in genetic medicines through fireside chats, individual company presentations, one-on-one meetings, and panel discussions . Get in touch if you would like to connect with Jean-Philippe […]
Join us at ESGCT 2025 in Sevilla
Join us at ESGCT 2025 in Sevilla for an important presentation by Jean-Philippe Combal from Vivet Therapeutics on October 9th at 10:00am CET during the session entitled Immune responses to gene therapy. https://lnkd.in/enSxNwzFLearn how VTX-PID (imlifidase) enables optimal depletion of anti-AAV3B neutralizing antibodies in human subjects, expanding eligibility for future systemic AAV-based gene therapies through innovative dose-ranging and […]
Two poster presentations at ESGCT 2025 in Sevilla
Vivet Therapeutics is excited to announce two poster presentations at ESGCT 2025 in Sevilla, showcasing innovative advances in liver-directed gene therapy. Catch us on Thursday, October 9th, from 14:00 to 15:30 CEST:
Our Pilot study of Cu64 data in Heterozygous Wilson’s Disease patients
We are excited to share our paper on Pilot clinical study showing abnormal copper metabolism in healthy Wilson disease heterozygote subjects, accepted to CTSJournal. See it here : https://lnkd.in/e-rzZnXp #ASCPTJournalFamily – Wilson Disease Association 64Cu has been used for decades to study WD, however clear data are lacking to document the rate of fecal elimination […]
ESGCT Sevilla
Vivet Therapeutics is delighted to announce its participation in the European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place in Sevilla, on October 7–10, 2025 (https://www.esgctcongress.com). On Thursday, October 9, Vivet will present new data on VTX-PID, highlighting compelling clinical results that demonstrate a reduction of neutralizing antibodies against AAV in naturally immunized populations. These findings have […]
AASLD – The Liver Meeting in Boston
Vivet Therapeutics is pleased to join AASLD – The Liver Meeting in Boston, MA this year. Meet with Vivet Therapeutics for an update on the GATEWAY gene therapy clinical trial for Wilson disease – booth B908
ESGCT’s 30th Annual Congress in Brussels
Excited to kick off ESGCT’s 30th Annual Congress in Brussels today! Join Vivet’s New Programs and Innovation Lead @Nicholas Weber, Ph.D. as he presents on the topic “Gene Therapy for Metabolic Diseases” on 25 October at 2:30 pm.
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics (“Vivet”), a clinical- stage biotechnology company
